Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 100%High 0 · 0%

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Overall survival · men with advanced prostate cancer

Non‐steroidal antiandrogen monotherapy probably leads to higher overall survival compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

1 finding from 1 review

Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
HR 1.24 [1.05, 1.48]
6 studies · 2712 participants
Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Clinical progression · men with advanced prostate cancer

Non‐steroidal antiandrogen monotherapy probably leads to higher clinical progression compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

1 finding from 1 review

Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
RR 1.26 [1.08, 1.45]
6 studies · 2373 participants
Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Treatment failure · men with advanced prostate cancer

Non‐steroidal antiandrogen monotherapy probably leads to higher treatment failure compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

1 finding from 1 review

Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
RR 1.27 [1.05, 1.52]
5 studies · 1845 participants
Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Breast pain · men with advanced prostate cancer

Non‐steroidal antiandrogen monotherapy probably leads to higher breast pain compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

1 finding from 1 review

Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
RR 22.97 [14.79, 35.67]
8 studies · 2670 participants
Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Gynaecomastia · men with advanced prostate cancer

Non‐steroidal antiandrogen monotherapy probably leads to higher gynaecomastia compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

1 finding from 1 review

Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
RR 8.43 [3.19, 22.28]
9 studies · 2774 participants
Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Hot flashes · men with advanced prostate cancer

Non‐steroidal antiandrogen monotherapy probably leads to lower hot flashes compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

1 finding from 1 review

Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
RR 0.23 [0.19, 0.27]
9 studies · 2774 participants
Moderate